NRXP December 13th Review

Longtime lurker, first time poster. NRXP was recently denied FDA approval for the breakthrough therapy designation for zyesami. The stock is currently trading under $5 with historical prices as high as $76. With covid continuing its rapid spread rates through Europe could we see more focus on treatments. The next meeting for the independent data safety and monitoring board is December 13th. This looks like a good entry point to me, but I’m new at this and would like others insight